Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Li, Bin ^a   Flaveny, Colin A ^a   Giambelli, Camilla ^a   Liang Fei, Dennis ^a   Han, Lu ^a   Hang, Brian I ^c   Bai, Feng ^a   Pei, Xin Hai ^a,b   Nose, Vania ^a   Burlingame, Oname ^a   Capobianco, Anthony J ^a,b   Orton, Darren ^d   Lee, Ethan ^c   Robbins, David J ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d StemSynergy Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASEIN KINASE IALPHA; CYCLIN D1; DICKKOPF 1 PROTEIN; PROTEIN P53; PYGOPUS2 PROTEIN; PYRVINIUM EMBONATE; UNCLASSIFIED DRUG; WNT1 PROTEIN; X BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIN2 GENE; CANCER INHIBITION; CCND1 GENE; CELL VIABILITY; COLON POLYPOSIS; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CTNNB1 GENE; DKK1 GENE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG REPOSITIONING; EMBRYO; ENZYME ACTIVATION; GASTROINTESTINAL POLYPOSIS; GENE REPRESSION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; LGR5 GENE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE; UNFOLDED PROTEIN RESPONSE; WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS COLI; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DRUG APPROVAL; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; HUMAN; TRANSGENIC MOUSE;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG APPROVAL; DRUG REPOSITIONING; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRVINIUM COMPOUNDS; WNT SIGNALING PATHWAY;

EID: 84903895414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101969     Document Type: Article

References (60)

1. Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, et al. (1993) Association of the APC gene product with beta-catenin. Science 262: 1731-1734.
2. Miller JR, Moon RT (1996) Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes & Development 10: 2527-2539.
3. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P (1998) Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8: 573-581.
4. van Noort M (2002) Wnt Signaling Controls the Phosphorylation Status of beta - Catenin. Journal of Biological Chemistry 277: 17901-17905.
5. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW (1997) Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 272: 24735-24738.
6. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA, et al. (1999) beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A 96: 6273-6278.
7. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, et al. (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 274: 10681-10684.
8. Kinzler K, Nilbert M, Su L, Vogelstein B, Bryan T, et al. (1991) Identification of Fap Locus Genes From Chromosome-5q21. Science 253: 661-665.
9. Nakamura Y, Nishisho I, Kinzler KW, Vogelstein B, Miyoshi Y, et al. (1991) Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symp 22: 285-292.
10. Cunningham C, Dunlop MG (1996) Molecular genetic basis of colorectal cancer susceptibility. Br J Surg 83: 321-329.
11. Panduro Cerda A, Lima Gonzalez G, Villalobos JJ (1993) Molecular genetics of colorectal cancer and carcinogenesis. Rev Invest Clin 45: 493-504.
12. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
13. Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, et al. (2010) Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis 25: 583-590.
14. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP (2010) The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212.
15. Lee KH, Li M, Michalowski AM, Zhang X, Liao H, et al. (2010) A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci U S A 107: 69-74.
16. Paoni NF, Feldman MW, Gutierrez LS, Ploplis VA, Castellino FJ (2003) Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse. Physiol Genomics 15: 228-235.
17. Groden J, Gelbert L, Thliveris A, Nelson L, Robertson M, et al. (1993) Mutational analysis of patients with adenomatous polyposis: identical inactivating mutations in unrelated individuals. Am J Hum Genet 52: 263-272.
18. Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, et al. (1993) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75: 951-957.
19. Jagelman DG (1991) Choice of operation in familial adenomatous polyposis. World J Surg 15: 47-49.
20. Ambroze WL Jr, Orangio GR, Lucas G (1995) Surgical options for familial adenomatous polyposis. Semin Surg Oncol 11: 423-427.
21. Church JM, Oakley JR, Wu JS (1996) Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis: report of a case. Dis Colon Rectum 39: 584-586.
22. Baba S (1998) Molecular biological background of FAP and HNPCC, and treatment strategies of both diseases depend upon genetic information. Nihon Geka Gakkai Zasshi 99: 336-344.
23. Wallace MH, Phillips RK (1998) Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 85: 742-750.
24. Wallace MH, Phillips RK (1999) Preventative strategies for periampullary tumours in FAP. Ann Oncol 10 Suppl 4: 201-203.
25. Okuno S (2006) The enigma of desmoid tumors. Curr Treat Options Oncol 7: 438-443.
26. Morgan GP (1995) NSAIDs and the chemoprevention of colon and oesophageal cancer. Gut 36: 153-154.
27. Santini DL, Rigas B, Shiff SJ (1999) Role of diet and NSAIDs in the chemoprevention of colorectal cancer. J Assoc Acad Minor Phys 10: 68-76.
28. Herendeen JM, Lindley C (2003) Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 37: 1664-1674.
29. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, et al. (2003) Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892.
30. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, et al. (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 124: 225-231.
31. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, et al. (2011) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4: 655-665.
32. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4: 29-42.
33. Keller JJ, Giardiello FM (2003) Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther 2: S140-149.
34. Paulsen JE, Namork E, Steffensen IL, Eide TJ, Alexander J (2000) Identification and quantification of aberrant crypt foci in the colon of Min mice - a murine model of familial adenomatous polyposis. Scand J Gastroenterol 35: 534-539.
35. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324.
36. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, et al. (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 6: 829-836.
37. Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E, et al. (2010) Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 5: e15521.
38. Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, et al. (2010) Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. Cancer Res 70: 6999-7009.
39. Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, et al. (2011) CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 470: 409-413.
40. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A 99: 8265-8270.
41. Gerlier D (1986) Use of MTT colorimetric assay to measure cell activation. Journal of immunological methods.
42. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nature Protocols 1: 2315-2319.
43. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, et al. (2013) Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2: e71.
44. Mazaki T, Ishii Y, Fujii M, Iwai S, Ishikawa K (1996) Mutations of p53, E-cadherin, alpha- and beta-catenin genes and tyrosine phosphorylation of beta-catenin in human gastric carcinomas. Int J Oncol 9: 579-583.
45. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH (2001) c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 61: 4910-4915.
46. Ramsay RG, Ciznadija D, Sicurella C, Reyes N, Mitchelhill K, et al. (2005) Colon epithelial cell differentiation is inhibited by constitutive c-myb expression or mutant APC plus activated RAS. DNA Cell Biol 24: 21-29.
47. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, et al. (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769-1775.
48. Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui Z-G, et al. (2006) Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. J Gastroenterol 41: 1053-1063.
49. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
50. Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, et al. (2003) Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 201: 250-259.
51. Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, et al. (2010) Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 123: 113-124.
52. de la Roche M, Ibrahim AE, Mieszczanek J, Bienz M (2014) LEF1 and B9L shield beta-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 74: 1495-1505.
53. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
54. Yu DH, Macdonald J, Liu G, Lee AS, Ly M, et al. (2008) Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One. 2008/12/17 ed. pp.e3951.
55. Venerando A, Girardi C, Ruzzene M, Pinna LA (2013) Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J 452: 131-137.
56. Goldberg MT (1984) Pyrvinium pamoate lacks in vivo genotoxicity in the colon. Toxicol Appl Pharmacol 74: 293-295.
57. Lake RS, Kropko ML, de la Iglesia FA (1982) Absence of in vitro genotoxicity of pyrvinium pamoate in sister-chromatid exchange, chromosome aberration, and HGPRT-locus mutation bioassays. J Toxicol Environ Health 10: 255-266.
58. Bandyopadhyay AK, Chowdhury AB (1966) Multiple dose therapy with pyrvinium pamoate in enterobiasis. Bull Calcutta Sch Trop Med 14: 134.
59. Blair LS, Thompson PE, Vandenbelt JM (1968) Effects of pyrvinium pamoate in the ration or drinking water of mice against pinworms Syphacia obvelata and Aspiculuris tetraptera. Lab Anim Care 18: 314-327.
60. Smith TC, Kinkel AW, Gryczko CM, Goulet JR (1976) Absorption of pyrvinium pamoate. Clin Pharmacol Ther 19: 802-806.